Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany

Cytotherapy

Volumn 9, Issue 4, 2007, Pages 397-405

  Schafer R ^a   Dominici, M ^b   Muller I ^a   Dazzi, F ^c   Bieback, K ^d   Godthardt, K ^e   Le Blanc, K ^f   Meisel, R ^g   Pochampally, R ^h   Richter, R ⁱ   Skutella, T ^j   Steinhoff, G ^k   Mitterberger, M ^l   Wendel, H P ^a   Wiskirchen, J ^a   Handgretinger, R ^a   Northoff, H ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MILTENYI BIOTEC GMBH   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^l UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DYNABEADS; INDOLEAMINE 2,3 DIOXYGENASE; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADRENOLEUKODYSTROPHY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOCOMPATIBILITY; BONE REGENERATION; BONE TURNOVER; CELL DIFFERENTIATION; CELL ISOLATION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS SURGERY; CULTURE TECHNIQUE; EMBRYONIC STEM CELL; ENGRAFTMENT; EPITHELIUM CELL; GRAFT VERSUS HOST REACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNE DEFICIENCY; IONIZING RADIATION; ISCHEMIC HEART DISEASE; LEUKODYSTROPHY; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STRESS INCONTINENCE; T LYMPHOCYTE; TISSUE ENGINEERING;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELLS, CULTURED; GERMANY; HEMATOPOIESIS; HUMANS; IMMUNOSUPPRESSION; STEM CELLS; STROMAL CELLS;

EID: 34347273033     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701392949     Document Type: Conference Paper

References (62)

1. Horwitz, EM, Prockop, DJ and Fitzpatrick, LA (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med, 5, pp. 309-313.
2. Horwitz, EM, Gordon, PL and Koo, WK (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA, 99, pp. 8932-8937.
3. Dominici, M., Pritchard, C. and Garlits, JE (2004) Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci USA, 101, pp. 11761-11766.
4. Colter, DC, Sekiya, I. and Prockop, DJ. (2001) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA, 98, pp. 7841-7845.
5. Kramer, J., Bohrnsen, F. and Lindner, U. (2006) In vivo matrix-guided human mesenchymal stem cells. Cell Mol Life Sci, 63, pp. 616-626.
6. Heckmann, L., Fiedler, J., Mattes, T. and Brenner, RE. (2006) Mesenchymal progenitor cells communicate via alpha and beta integrins with a three-dimensional collagen type I matrix. Cells Tissues Organs, 182, pp. 143-154.
7. Kassis, I., Zangi, L. and Rivkin, R. (2006) Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant, 37, pp. 967-976.
8. Friedenstein, AJ, Gorskaja, JF and Kulagina, NN. (1976) Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol, 4, pp. 267-274.
9. Vaananen, HK. (2005) Mesenchymal stem cells. Ann Med, 37, pp. 469-479.
10. Eslaminejad, MB, Nikmahzar, A. and Taghiyar, L. (2006) Murine mesenchymal stem cells isolated by low density primary culture system. Dev Growth Differ, 48, pp. 361-370.
11. Peister, A., Mellad, JA and Larson, BL (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood, 103, pp. 1662-1668.
12. Sun, S., Guo, Z. and Xiao, X. (2003) Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells, 21, pp. 527-535.
13. Smith, JR, Pochampally, R., Perry, A., Hsu, SC and Prockop, DJ. (2004) Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells, 22, pp. 823-831.
14. Dominici, M., Le, BK and Mueller, I. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, pp. 315-317.
15. - hematopoietic and mesenchymal stem cell subsets. Ann NY Acad Sci, 996, pp. 227-230.
16. Buhring, HJ, Kuci, S. and Conze, T. (2004) CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells, 22, pp. 334-343.
17. Guo, KT, Schafer, R. and Paul, A. (2006) A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA-aptamers. Stem Cells, 24, pp. 2220-2231.
18. Unger, EC. (2003) How can superparamagnetic iron oxides be used to monitor disease and treatment?. Radiology, 229, pp. 615-616.
19. Dick, AJ, Guttman, MA and Raman, VK (2003) Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in swine. Circulation, 108, pp. 2899-2904.
20. Luker, GD and Piwnica-Worms, D. (2001) Molecular imaging in vivo with PET and SPECT. Acad Radiol, 8, pp. 4-14.
21. Mahmood, U. and Weissleder, R. (2003) Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther, 2, pp. 489-496.
22. Bulte, JW, Douglas, T. and Witwer, B. (2001) Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol, 19, pp. 1141-1147.
23. Huber, MM, Staubli, AB and Kustedjo, K. (1998) Fluorescently detectable magnetic resonance imaging agents. Bioconjug Chem, 9, pp. 242-249.
24. Flacke, S., Fischer, S. and Scott, MJ (2001) Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation, 104, pp. 1280-1285.
25. Modo, M., Cash, D. and Mellodew, K. (2002) Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. Neuroimage, 17, pp. 803-811.
26. Daldrup-Link, HE, Rudelius, M. and Metz, S. (2004) Cell tracking with gadophrin-2: A bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging, 31, pp. 1312-1321.
27. Reimer, P., Weissleder, R. and Lee, AS (1990) Receptor imaging: application to MR imaging of liver cancer. Radiology, 177, pp. 729-734.
28. Yeh, TC, Zhang, W., Ildstad, ST and Ho, C. (1995) In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med, 33, pp. 200-208.
29. Schoepf, U., Marecos, EM and Melder, RJ (1998) Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques, 24, pp. 642-651.
30. Daldrup-Link, HE, Rudelius, M. and Piontek, G. (2005) Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: In vivo monitoring with 1.5-T MR imaging equipment. Radiology, 234, pp. 197-205.
31. Frank, JA, Miller, BR and Arbab, AS (2003) Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology, 228, pp. 480-487.
32. Hoehn, M., Kustermann, E. and Blunk, J. (2002) Monitoring of implanted stem cell migration in vivo: A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA, 99, pp. 16267-16272.
33. Pintaske, J., Helms, G. and Bantleon, R. (2005) A preparation technique for quantitative investigation of SPIO-containing solutions and SPIO-labelled cells by MRI. Biomed Tech (Berl), 50, pp. 174-180.
34. Pintaske, J., Bantleon, R. and Kehlbach, R. (2006) Effect of concentration of SH U 555A labeled human melanoma cells on MR spin echo and gradient echo signal decay at 0.2, 1.5 and 3T. MAGMA, 19, pp. 71-77.
35. Metz, S., Bonaterra, G. and Rudelius, M. (2004) Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol, 14, pp. 1851-1858.
36. Bulte, JW, Kraitchman, DL, Mackay, AM and Pittenger, MF. (2004) Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood, 104, pp. 3410-3412.
37. Goldman, JM, Gale, RP and Horowitz, MM (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med, 108, pp. 806-814.
38. Peggs, KS and Mackinnon, S. (2004) Immune reconstitution following haematopoietic stem cell transplantation. Br J Haematol, 124, pp. 407-440.
39. Pittenger, MF, Mackay, AM and Beck, SC (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, pp. 143-147.
40. Barry, FP, Boynton, RE and Haynesworth, S. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun, 265, pp. 134-139.
41. Barry, F., Boynton, R. and Murphy, M. (2001) The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun, 289, pp. 519-524.
42. Nicola, M Di, Carlo-Stella, C. and Magni, M. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, pp. 3838-3843.
43. Bartholomew, A., Sturgeon, C. and Siatskas, M. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 30, pp. 42-48.
44. Krampera, M., Glennie, S. and Dyson, J. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101, pp. 3722-3729.
45. Glennie, S., Soeiro, I. and Dyson, PJ (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105, pp. 2821-2827.
46. Ramasamy, R., Lam, EW and Soeiro, I. (2006) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia, 21, pp. 304-310.
47. Zappia, E., Casazza, S. and Pedemonte, E. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 106, pp. 1755-1761.
48. Blanc, K Le, Rasmusson, I. and Sundberg, B. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, pp. 1439-1441.
49. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med, 9, pp. 1144-1150.
50. Schmaltz, C., Alpdogan, O. and Horndasch, KJ (2001) Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood, 97, pp. 2886-2895.
51. Zhang, J. and Niu, C. (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature, 425, pp. 836-841.
52. Dazzi, F., Ramasamy, R. and Glennie, S. (2006) The role of mesenchymal stem cells in haemopoiesis. Blood Rev, 20, pp. 161-171.
53. Kaplan, RN, Riba, RD and Zacharoulis, S. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, pp. 820-827.
54. Meisel, R., Zibert, A. and Laryea, M. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103, pp. 4619-4621.
55. Plumas, J., Chaperot, L. and Richard, MJ (2005) Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia, 19, pp. 1597-1604.
56. Krampera, M., Cosmi, L. and Angeli, R. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24, pp. 386-398.
57. Munn, DH, Zhou, M. and Attwood, JT (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281, pp. 1191-1193.
58. Uyttenhove, C., Pilotte, L. and Theate, I. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med, 9, pp. 1269-1274.
59. Muller, I., Kordowich, S. and Holzwarth, C. (2006) Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy, 8, pp. 437-444.
60. Muller, I., Kustermann-Kuhn, B. and Holzwarth, C. (2006) In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients. Exp Hematol, 34, pp. 1413-1419.
61. - stem cells that give rise to SCID-repopulating cells. Blood, 101, pp. 869-876.
62. Shultz, LD, Lyons, BL and Burzenski, LM (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol, 174, pp. 6477-6489.